Abstract |
In 40 patients presenting with Duchenne muscular dystrophy, a double blind therapeutic trial of 18 months was undertaken in order to appreciate the efficacy of pizotifen, an anti-serotoninergic drug. Quarterly evaluations were performed. Each of them included muscular testing on 31 pairs of muscles, timed tests, dynamometric study of the thumb-forefinger grip, functional testing, respiratory function tests, muscular enzyme determinations, parents' subjective estimation and search for side-effects. With respect to the evolution of Duchenne muscular dystrophy, this study did not show significant differences between pizotifen at a dose of 1.5 mg/day and placebo, except for a parents' preference for the drug.
|
Authors | D Steru, J P Paclet, G Barthelet, G Gailliard, A Piton, E Monchartre, R Roche, J Galli, S Lancrenon, J Fermanian |
Journal | Archives francaises de pediatrie
(Arch Fr Pediatr)
1987 Jun-Jul
Vol. 44
Issue 6
Pg. 461-5
ISSN: 0003-9764 [Print] France |
Vernacular Title | Etude en double aveugle de l'efficacité d'un antisérotoninergique, le pizotifène, dans la myopathie de Duchenne de Boulogne. |
PMID | 3619586
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Child
- Child, Preschool
- Double-Blind Method
- Humans
- Male
- Muscle Contraction
(drug effects)
- Muscular Dystrophies
(drug therapy, genetics)
- Pizotyline
(pharmacology, therapeutic use)
- Respiratory Function Tests
- Thiophenes
(therapeutic use)
|